Back to results
US 2021/0230209 A1Published application
Amp-activated protein kinase activating compounds and uses thereof
AssigneeSkylark Bioscience LLC
InventorOliver SAUNDERS
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions associated with activation of AMP-activated protein kinase, wherein the compound is of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such compounds, as well as methods to use these positions for treating indications including cancer, diabetes, ischemic injury, obesity, hyperlipidemia, and cardiac conditions.
Claims19
A compound of Formula (I):
- wherein:
- R1 is selected from:
- (a) C1-C6 alkyl substituted with one or more groups selected from list X;
- (b) Q;
- and
- (c) -L-Q;
- R2 is selected from:
- (a) H;
- (b) Q;
- and
- (c) -L-Q;
- and
- Q is independently selected at each occurrence and represents a ring selected from phenyl and a 5-6 membered heteroaryl containing one to three heteroatoms selected from N, O and S as ring members, and each Q is optionally substituted with one to three groups selected from List M;
- L is C1-C4 alkylene optionally substituted with one or two groups selected from halo, oxo (═O), —OH, C1-C2 haloalkyl, C1-C2 alkoxy, C1-C2 haloalkoxy, CN, COOR7, —OC(═O)R7, and NR8R9;
- R3 is H or —C(═O)—R6;
- R4 is H or —C(═O)—R6;
- R6 is H or C1-C6 alkyl that is optionally substituted with one to three groups selected from halo, CN, hydroxy, C1-C4 alkoxy, C1-C4 haloalkyl, —NR8R9, —OC(═O)—R7, and COOR7;
- R7 is independently selected at each occurrence from H and C1-C6 alkyl optionally substituted with up to three groups selected from halo, CN, hydroxy, C1-C4 alkoxy, and C1-C4 haloalkyl;
- R8 and R9 are each independently selected at each occurrence from H and C1-C4 alkyl optionally substituted with one or two groups selected from List X;
- or R8 and R9 taken together with the Nitrogen to which both are attached form a 5-6 membered heterocyclic ring optionally containing an additional heteroatom selected from N, O and S as a ring member, and optionally substituted with one to four groups selected from halo, oxo, C1-C2 alkyl, hydroxy, C1-C2 alkoxy, CN, and COOR7;
- R10 is independently at each occurrence C1-C6 alkyl optionally substituted with up to three groups selected from halo, CN, hydroxy, C1-C4 alkoxy, and C1-C4 haloalkyl;
- List X consists of halo, CN, —OH, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, ═O, —COOR7, —OC(═O)R7, —O—COOR10, —SO2R10, —SO2NR8R9, —O-Q, and —O-L-Q;
- List M consists of halo, CN, NO2, COOR7, CONR8R9, —SO2R10, —SO2NR8R9, C1-C2 haloalkyl, C1-C2 haloalkoxy, C1-C2 alkoxy, and C1-C2 alkyl;
- or a pharmaceutically acceptable salt thereof.
21 more elements
Dependencies are inferred from the claim text.